Skip to content
‹ Back to IndustriesSciences

Falling Space Station Will Hit Earth

China’s 8.5-ton space station will come crashing down to Earth from Saturday onwards, the country’s space authorities said, although they can not confirm where it is likely to hit. The Tiangong-1, or “Heavenly Palace” lab, will hit the earth between March 31 and April 4 and “should” burn up in the atmosphere, Chinese space officials…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share
Falling Space Station Will Hit Earth

Key takeaways

01

China’s 8.5-ton space station will come crashing down to Earth from Saturday onwards, the country’s space authorities said, although they can not confirm where it is likely to hit.

02

The Tiangong-1, or “Heavenly Palace” lab, will hit the earth between March 31 and April 4 and “should” burn up in the atmosphere, Chinese space officials…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

China’s 8.5-ton space station will come crashing down to Earth from Saturday onwards, the country’s space authorities said, although they can not confirm where it is likely to hit.

The Tiangong-1, or “Heavenly Palace” lab, will hit the earth between March 31 and April 4 and “should” burn up in the atmosphere, Chinese space officials said this week.

China’s first space lab was launched in 2011 and had “comprehensively fulfilled its historical mission” five years later.

It had ceased sending data and entered its “final phase of life” on March 16, according to a notice issued by the China Manned Space Engineering Office.

It is currently orbiting at an average height of about 216.2 kilometres, but experts are still unclear about the exact location of re-entry.

“It is impossible to name the exact reentry location at this stage”, an unnamed expert told the state-run Global Times newspaper.

Read the full article here

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Why shared auto-injectors keep forcing rebuilt device files

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight co-founder Fubin Wu cites digitalization, personalization and large-volume delivery as trends reshaping drug delivery devices, arguing structured data can enable reuse and cut duplicated design-file work for shared auto-injectors. ISPE says no regulatory pathway exists for platform devices, and ONdrugDelivery counts 182 large-volume subcutaneous biologics, about 15% of IV and SC agents.

  • 01A device shared across drug products still triggers repeated design control work for each new combination product, and ISPE's November 2025 article says no regulatory pathway yet exists to approve a platform device.
  • 02FDA's May 2024 draft platform technology designation under section 506K is written for drug product applications, so device design files sit outside it.
  • 03Large-volume subcutaneous biologics above 2 mL numbered 182 in a January 2025 ONdrugDelivery review, about 15% of IV and SC agents; Advanced Drug Delivery Reviews reported in July 2026 that volumes up to 25 mL are now pursued.

Oct 22, 2026

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan prefilled syringe plant in Shenzhen won the Innovation (Novel Technology) category at ISPE's 2026 Facility of the Year Awards. In the transcript ISPE posted with its podcast, CaiXue Wei describes vertical design, AGV-assisted transfer, AI inspection and 5G-MEC as one integrated system built around a 330 million-syringe annual capacity; Hepalink's own release adds a 24-meter warehouse, sub-10 millisecond 5G and 24,000-unit-an-hour inspection.

  • 01Hepalink's 24-meter automated warehouse raised space utilization 52 percent over a traditional layout on a land-scarce Shenzhen site supporting 330 million syringes a year.
  • 02AGVs pass material through vaporized hydrogen peroxide chambers straight into Grade A isolators, and Hepalink credits the zero-touch flow for a 100 percent first media fill.

Oct 22, 2026

Chalmers' AI scientist turned 60,000 yeast records into nearly 2,000 testable ideas

Chalmers' AI scientist turned 60,000 yeast records into nearly 2,000 testable ideas

Chalmers University of Technology's AI scientist Eve analyzed about 60,000 public yeast records, came up with almost 2,000 testable ideas, and took full charge of planning the experiments and telling other robots what to do, according to CORDIS. Humans handled safety checks and plate moving.

  • 01The key step for company labs is translation: turning hypotheses into machine-executable protocols and getting contextualized results back to the reasoning layer fast.

Oct 19, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512